| abstract |
Disclosed are a chondroitinase gene variant, a polypeptide and protein derived therefrom, and a method for promoting neurological functional recovery after a disorder or disease of the central nervous system. A soluble NOGO antagonist, a neuronal adhesion factor, a neurotrophic factor, a growth factor, a phosphodiesterase inhibitor, and an inhibitor of MAG or MOG, neuregulin, and a component selected from an antibody that promotes remyelination. Provided is a method for treating central nervous system injury or disease using a fusion protein having a purified chondroitinase AC mutant polypeptide. [Selection] Figure 7 |